Lupin Launches Authorized Generic Version of Brovana® in the United States

Global pharma major, Lupin Limited (Lupin), announced the launch of the authorized generic version of Brovana® (arformoterol tartrate) Inhalation Solution 15 mcg*/2 mL, unit-dose vials, of Sunovion Pharmaceuticals Inc.

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL, is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is for use by nebulization only.

Shares of LUPIN LTD. was last trading in BSE at Rs.1232.35 as compared to the previous close of Rs. 1246.9. The total number of shares traded during the day was 85692 in over 3971 trades.

The stock hit an intraday high of Rs. 1256.9 and intraday low of 1226.05. The net turnover during the day was Rs. 106123509.

*potency expressed as arformoterol

Source : Equity Bulls

Keywords